ERBB2 and breast carcinoma: As expected, HER2 KD or lapatinib, a HER2 inhibitor, decreased the RNF126 mRNA and protein levels in the HER2‐positive breast cancer cell line BT474 (Figure S6A–C, Supporting Information).